QUOTE AND NEWS
Benzinga  Oct 2  Comment 
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today announced the initiation of the SOLUTION (Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in People With Cystic Fibrosis) Phase 3 clinical study evaluating the efficacy and...
Benzinga  Sep 17  Comment 
Anthera Pharmaceuticals Inc (NASDAQ: ANTH) shares are down 5 percent since August 18, remaining below the $10 mark. Citi’s Yigal Nochomovitz initiated coverage of the company with a Buy rating and a price target of $15. Although the...
Benzinga  Sep 17  Comment 
Analysts at Citigroup initiated coverage of Anthera Pharmaceuticals Inc (NASDAQ: ANTH) with a Buy rating. The target price for Anthera Pharmaceuticals is set to $15. Anthera Pharmaceuticals shares closed at $7.98 on Wednesday. Analysts at Euro...
FierceBiotech  Sep 15  Comment 
Anthera Pharmaceuticals is back on the hunt for a partner in Asia after Japanese drugmaker Zenyaku pulled the plug on the pair's collaboration, clouding the future for the company's lupus drug.
Benzinga  Jul 14  Comment 
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), today announced that it has completed the previously announced underwritten public offering of 3,833,334 shares of its common stock, offered at a price of $7.50 per share, which includes the exercise...
TheStreet.com  Jul 9  Comment 
NEW YORK (TheStreet) -- Shares of Anthera Pharmaceuticals Inc. were dropping, sharply down 7.43% to $7.72 on heavy volume in late morning trading Thursday, after the company priced its underwritten public offering this morning. The...
Benzinga  Jul 9  Comment 
Anthera Pharmaceuticals Inc (NASDAQ: ANTH) fell 7.67 percent to $7.70 in pre-market trading after the company reported a proposed offering of common stock. AIXTRON SE (ADR) (NASDAQ: AIXG) shares declined 7.59 percent to $5.97 in pre-market...
Benzinga  Jul 8  Comment 
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an...




 
TOP CONTRIBUTORS

Anthera Pharmaceuticals (ANTH) (NASDAQ:ANTH) is a pharmaceutical company developing drug treatments for respiratory, cardiovascular, and immunological diseases. Its current products in development are therapies for the inflammation of heart muscle, lupus, and sickle cell disease.

For pharmaceutical drugs to reach the market, it must pass three stages of FDA approval process. Anthera's lead product candidate A-002, a drug to treat symptoms of shortage of oxygen to the heart (acute coronary syndrome), has completed the second stage for FDA approval. [1] The 2009 market size is valued at $1 billion. [2]

The company's initial public offering of stock was filed on 16 September 2009 and is expected to begin trading on the week of February 22. The proposed offer price range is $13-$15. The company offered 4.6 million shares. [1]

In the FY 2009 ending 31 December 2009, it reported $11.8 million in operating expenses, down 14.8% from $13.86 million in operating expenses in 2008. The company has not incurred any revenues, and it cannot incur any revenues until it receives regulatory and commercial licenses for its products. [1]

References

  1. 1.0 1.1 1.2 Anthera S-1/A
  2. Market Research
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki